ArticleCancer immunology, immunotherapy : CII2018
IL-10 inducible CD8
Article in Cancer immunology, immunotherapy : CII, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 26 citations in OpenAlex.
- CD8Leukemia · 2024Trial
- Special Issue "Role of Immune Cells in Non-Infectious Inflammatory Diseases and Cancers".International journal of molecular sciences · 2026Article
- Review
- Regulatory T Cell-Based Adoptive Cell Therapy in Autoimmunity.International journal of molecular sciences · 2025Review
- T Cells Dysfunction in Multiple Myeloma.ImmunoTargets and therapy · 2025Review
- SLAMF7 (CD319) enhances cytotoxic T-cell differentiation and sensitizes CD8Frontiers in immunology · 2025Article
- High proportion of circulating CD8 + CD28- senescent T cells is an independent predictor of distant metastasis in nasopharyngeal canrcinoma after radiotherapy.Journal of translational medicine · 2023Article
- Tumor promoting roles of IL-10, TGF-β, IL-4, and IL-35: Its implications in cancer immunotherapy.SAGE open medicine · 2022Review
- Multiple Myeloma-Derived Extracellular Vesicles Modulate the Bone Marrow Immune Microenvironment.Frontiers in immunology · 2022Article
- CAR T-cell immunotherapy: a powerful weapon for fighting hematological B-cell malignancies.Frontiers of medicine · 2021Review
- Accumulation of CD28Biomolecules · 2021Review
- Selective elimination of immunosuppressive T cells in patients with multiple myeloma.Leukemia · 2021Article
- T Cell Transcriptional Profiling and Immunophenotyping Uncover LAG3 as a Potential Significant Target of Immune Modulation in Multiple Myeloma.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation · 2020Article
- Effect of early restrictive fluid resuscitation on inflammatory and immune factors in patients with severe pelvic fracture.Chinese journal of traumatology = Zhonghua chuang shang za zhi · 2019Article
- Versican proteolysis predicts immune effector infiltration and post-transplant survival in myeloma.Leukemia & lymphoma · 2019Article
- The Evolving Role of CD8International journal of molecular sciences · 2019Review
- The perspectives of interleukin-10 in the pathogenesis and therapeutics of multiple myeloma.Tzu chi medical journalReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tumor-mediated immunosuppression via regulatory T-cells is a key player among the various immune-escape mechanisms in multiple myeloma. We analyzed the generation, distribution, function and immunophenotype of CD8
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.